Drug, across the briefings

Sorafenib across 5 cancers

Sorafenib appears in 5 of the briefings; its FDA label names 1 of those diseases.

Disease	FDA label	Open Targets stage, on which gene	Trials	Active
Hepatocellular carcinoma	label names disease	approved on KDR	175	11
Acute myeloid leukemia		approved on FLT3, KIT	53	15
Colorectal cancer		approved on BRAF	19	0
Lung cancer		approved on BRAF, RET	44	0
Melanoma		approved on BRAF, KIT	30	1

The label column is the briefing's openFDA stage: a label whose Indications and Usage names the disease. The Open Targets column is the furthest clinical stage recorded for the drug against any gene on that briefing's target list, in any indication. Trials are ClinicalTrials.gov interventional studies naming the drug and the disease, from the briefing's trials stage; a dash means the briefing did not search this drug in that disease (it searches the drugs Open Targets lists against its own genes), which is not the same as none. Salt forms, biosimilar suffixes and formulation words are merged by the same rule the briefings use.